MedWatch

Gubra awarded grant to develop smart insulin: "We'll become 3-4 times faster"

Gubra has received a research grant from diabetes organization JDRF in order to develop a new type of insulin with the potential to revolutionize the treatment of type 1 diabetes and make other types of insulin obsolete. According to CSO Keld Fosgerau, the project can be expanded to maximize value before getting a partner on board.

Keld Fosgerau, Chief Science Officer, Gubra. | Foto: Gubra/PR

Danish biotech company and contract research organization Gubra has entered a new partnership with global diabetes organization JSRF to develop of new type of 'smart' insulin, which has the potential to render obsolete the current mealtime insulin and basal insulin used to treat insulin-dependent diabetes.

"It is quite simply a new type of insulin," says Gubra Chief Science Officer Keld Fosgerau to MedWatch.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier